Status:
COMPLETED
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
Lead Sponsor:
University Hospital, Limoges
Conditions:
Recurrent Pregnancy Losses
Preeclampsia
Eligibility:
FEMALE
18-45 years
Brief Summary
Justification: We have recently demonstrated that maternofetal alloimmunization was not limited to blood cells: maternal alloimmunization against a glomerular podocyte antigen expressed by the placen...
Eligibility Criteria
Inclusion
- Recurrent pregnancy losses : patient having or having suffered from at least 3 consecutive, unexplained recurrent pregnancy losses, during the first 3 months of pregnancy, with the same paerson/man.
- Preeclampsia : blood pressure \> 140/90 mm Hg ; proteinuria \> 0,3 g/ 24 h
- Intervillositis : patient suffering or having suffered from intervillositis
Exclusion
- Recurrent pregnancy losses : uterine pathology, endocrine pathology, autoimmune pathology, coagulation and hemostasis pathology, karyotype anomaly.
- Preeclampsia : pre-existing high blood pressure, pre-existing diabetes, pre-existing renal disease, antiphospholipid antibodies syndrome
- Intervillositis : intervillositis with villositis
Key Trial Info
Start Date :
September 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00456118
Start Date
September 1 2006
End Date
December 1 2009
Last Update
August 13 2018
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Bordeaux University Hospital
Bordeaux, France, 33076
2
LIMOGES University Hospital
Limoges, France, 87042
3
Saint Antoine Hospital
Paris, France, 75012
4
Tenon Hospital
Paris, France, 75020